Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must have schizophrenia~* Patients must be clinically stable on antipsychotic medication~* Patients must be retrospectively judged by investigators, based on clinical interview and impression, to have been stable (with respect to their symptoms of schizophrenia) for at least 4 weeks entry into the study~* Patients must be an outpatient and have BPRS positive items scores of 4 or less to enter the study~* Female patients of childbearing potential must be using a medically accepted means of contraception.~Exclusion Criteria:~* Patients must not have participated in a clinical trial of another investigational drug, including olanzapine, within 1 month (30 days) prior to study entry.~* Female patients must not be pregnant or breast-feeding~* Patients must not be experiencing acute, serious, or unstable medical conditions other than schizophrenia~* Patients must not require concomitant treatment with any other medication with primarily central nervous system activity, including antidepressants, mood stabilizers, and anticonvulsants.~* Patients must not have a substance (except nicotine or caffeine) dependence within the past 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).